Vaishali Pharma’s H1 FY24 Revenue Up By 9%

Mumbai (Maharashtra) [India], November 10: Vaishali Pharma Limited (NSE – VAISHALI), engaged in production and marketing of a diverse range of pharmaceutical products, announced its unaudited Financial Results for H1 & Q2 FY24.

Key Financials at a Glance:

H1 FY24:

• Total Income at ₹ 26.65 Cr

• EBITDA at ₹ 5.62 Cr

• EBITDA Margin is 21.11 %

• Net Profit at ₹ 3.29 Cr

• Net Profit Margin is 12.34%

• EPS at ₹ 3.10

Q2 FY24:

• Total Income at ₹ 12.86 Cr

• EBITDA at ₹ 2.95 Cr

• EBITDA Margin is 22.97 %

• Net Profit at ₹ 1.70 Cr

• Net Profit Margin is 13.24 %

• EPS at ₹ 1.61

Commenting on the performance, Mr. Atul Vasani, Chairman and Managing Director of Vaishali Pharma Limited said, “We are pleased to present the results for H1 of FY24. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success.

Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide.”

If you have any objection to this press release content, kindly contact to notify us. We will respond and rectify the situation in the next 24 hours.